BR112012028153A2 - composição farmacêutica e método para o tratamento de hipertensão - Google Patents

composição farmacêutica e método para o tratamento de hipertensão

Info

Publication number
BR112012028153A2
BR112012028153A2 BR112012028153A BR112012028153A BR112012028153A2 BR 112012028153 A2 BR112012028153 A2 BR 112012028153A2 BR 112012028153 A BR112012028153 A BR 112012028153A BR 112012028153 A BR112012028153 A BR 112012028153A BR 112012028153 A2 BR112012028153 A2 BR 112012028153A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
hypertension
treating hypertension
treating
dextromethorphone
Prior art date
Application number
BR112012028153A
Other languages
English (en)
Portuguese (pt)
Inventor
Wang Hsi-Chieh
Chen Jaw-Wen
Juang Shin-Yi
Original Assignee
Tsh Biopharm Corporation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tsh Biopharm Corporation Ltd filed Critical Tsh Biopharm Corporation Ltd
Publication of BR112012028153A2 publication Critical patent/BR112012028153A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112012028153A 2010-05-03 2011-04-29 composição farmacêutica e método para o tratamento de hipertensão BR112012028153A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33054010P 2010-05-03 2010-05-03
PCT/CN2011/073560 WO2011137734A1 (en) 2010-05-03 2011-04-29 Pharmaceutical composition and method for treating hypertension

Publications (1)

Publication Number Publication Date
BR112012028153A2 true BR112012028153A2 (pt) 2018-08-07

Family

ID=44903590

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012028153A BR112012028153A2 (pt) 2010-05-03 2011-04-29 composição farmacêutica e método para o tratamento de hipertensão

Country Status (11)

Country Link
US (2) US20130053411A1 (https=)
EP (1) EP2566478A4 (https=)
JP (1) JP5847162B2 (https=)
KR (1) KR20130061148A (https=)
CN (1) CN102869360B (https=)
AU (1) AU2011250485B2 (https=)
BR (1) BR112012028153A2 (https=)
MY (1) MY161853A (https=)
RU (1) RU2571284C2 (https=)
TW (1) TWI583383B (https=)
WO (1) WO2011137734A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6301371B2 (ja) * 2013-02-14 2018-04-11 ノバルティス アーゲー インビボ効力が改善されたｎｅｐ阻害剤としての置換ビスフェニルブタン酸誘導体
US20160317542A1 (en) 2013-12-09 2016-11-03 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
TW201717947A (zh) * 2015-08-20 2017-06-01 漢達生技醫藥股份有限公司 包含氨氯地平和右美沙芬的藥物組合物
MX2019006938A (es) 2016-12-14 2019-09-06 Respira Therapeutics Inc Metodos y composiciones para trataminto de hipertension pulmonar y otros trastornos del pulmon.
SI4101454T1 (sl) 2017-01-25 2024-10-30 The George Institute for Global Health Sestavki za uporabo pri zdravljenju hipertenzije
US12521380B2 (en) 2017-01-25 2026-01-13 The George Institute for Global Health Compositions for the treatment of hypertension

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2676177A (en) 1949-11-09 1954-04-20 Hoffmann La Roche Process for the preparation of optically active 3-methoxy-n-methyl morphinans and salts thereof
GB8710493D0 (en) 1987-05-02 1987-06-03 Pfizer Ltd Dihydropyridines
WO1992003137A1 (en) * 1990-08-23 1992-03-05 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy, peripheral neuropathy, and vision loss
JPH04368338A (ja) * 1991-06-12 1992-12-21 Taisho Pharmaceut Co Ltd 鎮咳剤
US5350756A (en) * 1991-06-17 1994-09-27 Smith Richard A Use of a cytochrome oxidase inhibitor to increase the cough-suppressing activity of dextromorphan
US6057344A (en) 1991-11-26 2000-05-02 Sepracor, Inc. Methods for treating hypertension, and angina using optically pure (-) amlodipine
US5560913A (en) 1995-01-27 1996-10-01 The Procter & Gamble Company Pharmaceutical compositions
US7662826B2 (en) 2002-04-23 2010-02-16 Shionogi & Co., Ltd. Pyrazolo [1,5-a] pyrimidine derivative and nad (p) h oxidase inhibitor containing the same
CA2486157C (en) * 2002-05-17 2013-04-16 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US7923454B2 (en) 2002-05-17 2011-04-12 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
TWI326214B (en) * 2002-07-17 2010-06-21 Avanir Pharmaceuticals Inc Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
KR100476636B1 (ko) 2002-09-11 2005-03-17 한림제약(주) 엘-(+)-타르트레이트를 이용한 에스-(-)-암로디핀의 제조방법
CL2003002653A1 (es) * 2002-12-18 2005-04-22 Wyeth Corp Composicion farmaceutica que comprende (a) un antiinflamatorio no esteroidal (nsaid), preferentemente ibuprofeno, (b) un descongestionante, preferentemente pseudoefedrina y (c) un antihistaminico, preferentemente clorfeniramina; metodo para su prepar
WO2006033965A2 (en) 2004-09-16 2006-03-30 The Trustees Of The University Of Pennsylvania Nadph oxidase inhibition pharmacotherapies for obstructive sleep apnea syndrome and its associated morbidities
US20060188450A1 (en) * 2005-02-24 2006-08-24 Tim Clarot System and method for suppressing a cough
US7939567B2 (en) * 2006-02-24 2011-05-10 Blue Blood Biotech Corp. Dextromethorphan-based method for treating acne
US7820689B2 (en) 2006-08-10 2010-10-26 Hua-Lin Wu Methods and compositions for preventing or treating cardiovascular disease
US8569364B2 (en) * 2007-11-28 2013-10-29 Sequoia Pharmaceuticals, Inc. 5-substituted benzofurans as inhibitors of cytochrome P450 2D6

Also Published As

Publication number Publication date
US20160235741A1 (en) 2016-08-18
MY161853A (en) 2017-05-15
CN102869360A (zh) 2013-01-09
JP2013525460A (ja) 2013-06-20
WO2011137734A1 (en) 2011-11-10
RU2571284C2 (ru) 2015-12-20
EP2566478A4 (en) 2014-04-30
KR20130061148A (ko) 2013-06-10
AU2011250485A1 (en) 2012-12-06
US20130053411A1 (en) 2013-02-28
EP2566478A1 (en) 2013-03-13
JP5847162B2 (ja) 2016-01-20
US9744165B2 (en) 2017-08-29
TWI583383B (zh) 2017-05-21
CN102869360B (zh) 2015-03-25
RU2012151051A (ru) 2014-06-10
TW201206437A (en) 2012-02-16
AU2011250485B2 (en) 2016-07-07

Similar Documents

Publication Publication Date Title
BR112015009948A8 (pt) Antagonistas de ativina-actrii, usos dos mesmos para tratamento de doenças ósseas e outros distúrbios e método para monitorar a eficácia do tratamento ou prevenção de uma doença óssea e outros distúrbios
DK1970059T3 (da) Lægemiddel med calciumdobesilat til behandling og profylakse af senelidelser
BR112015007878A2 (pt) composto compreendendo oligonucleotídeo modificado, composição, combinação e uso dos mesmos
PH12013501790B1 (en) Use of dpp iv inhibitors
SV2011003901A (es) Compuestos de arilo con sustituyentes heterocíclicos como inhibidores de hif
MX385174B (es) Terapia antidiabética vasoprotectora y cardioprotectora.
PL385586A1 (pl) Nowe analogi insuliny o przedłużonym działaniu
EA201170349A1 (ru) Модуляторы mif
BR112014024793A2 (pt) método de inibição da ativação do complemento dependente de masp-3, e, composição farmacêutica.
BR112012028153A2 (pt) composição farmacêutica e método para o tratamento de hipertensão
CO6300844A2 (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasa
BR112012006468A2 (pt) métodos de tratamento de inflamação
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
UY33221A (es) MÉTODOS PARA TRATAR CÁNCER USANDO INHIBIDORES DE PI3K Y mTOR EN COMBINACIÓN CON INHIBIDORES DE AUTOFAGIA
BR112014020113A8 (pt) Composições farmacêuticas e método para diminuir a frequência de micção
WO2008112773A3 (en) Droxidopa and pharmaceutical composition thereof for the treatment of neurally mediated hypotension
WO2014071168A3 (en) Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients
BR112013022217A2 (pt) composição farmacêutica, método de tratamento preventivo de uma síndroma hemorrágica em um paciente com hemofilia a ou b e método de tratamento de um acidente hemorrágico em um paciente com hemofilia a ou b
BR112012033349A2 (pt) tratamento de queloide
EA201200428A1 (ru) Композиция и способ для лечения ожирения
BR112012006070A2 (pt) composições e métodos para tratar distúrbios convulsivos.
BR112015001627A2 (pt) composição farmacêutica, respectivos usos e método para diminuir a frequência de micção
TN2010000266A1 (en) Oxazolidinones for the treatment and/or prophylaxis of heart failure
BR112016017496A2 (pt) Composição para acelerar a penetração através da pele, preparação para administração transdérmica e preparação de emplastro de pele
BR112013024525A2 (pt) compostos, composição farmacêutica e métodos para tratar condição pré-cancerosa ou câncer em mamífero, pacientes com doença inflamatória crônica ou doença neurodegenerativa e para preparar compostos e usos de compostos e de composição farmacêutica

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2484 DE 14-08-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.